Effect of Bushen Huoxue traditional Chinese medicine in the treatment of hyperosteogeny secondary low back pain and influence on bone sclerosis protein level of patients
WANG Zai-feng
Erbozi Community Health Service Station,Huilongguan Community Health Service Center in Changping District of Beijing City,Beijing 102208,China
Abstract:Objective To investigate the effect of Bushen Huoxue traditional Chinese medicine in the treatment of hyperosteogeny secondary low back pain and influence on bone sclerosis protein(SOST)level of patients.Methods Eighty cases of patients with hyperosteogeny secondary low back pain from May 2015 to May 2017 treated in our station were randomly selected,and patients were divided into the single Western Medicine group (n=40)and Western Medicine combined with Chinese herbal group(combination of Traditional Chinese and Western Medicine group,n=40)according to the treatment methods.TCM syndrome score,clinical effect and SOST level were compared in patients between the two groups were compared.Results The score of joint and muscle pain,soreness and weakness of waist and knees,unfavourable flexion and extension,intolerance to cold and cold limbs,weak or breakdowning pulse,thin white or atrazine coating on the tongue in patients of combination of Traditional Chinese and Western Medicine group were significantly lower than those of single Western Medicine group(P<0.05),and the total effective rate(90.0%)was significantly higher than that of the Western Medicine group(40.0%)(P<0.05),and the level of SOST was significantly higher than that of the single Western Medicine group(P<0.05).ConclusionThe effect of Bushen Huoxue traditional Chinese medicine in the treatment of hyperosteogeny secondary low back pain is significant,and it can effectively raise the SOST level of patients.
王在凤. 补肾活血中药治疗骨质增生继发性腰痛的效果及对患者骨硬化素蛋白水平的影响[J]. 中国当代医药, 2018, 25(8): 158-160.
WANG Zai-feng. Effect of Bushen Huoxue traditional Chinese medicine in the treatment of hyperosteogeny secondary low back pain and influence on bone sclerosis protein level of patients. 中国当代医药, 2018, 25(8): 158-160.